These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 11892686)

  • 1. Measuring treatment effects of cilostazol on clinical trial endpoints in patients with intermittent claudication.
    Smith JA
    Clin Cardiol; 2002 Mar; 25(3):91-4. PubMed ID: 11892686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study.
    Strandness DE; Dalman RL; Panian S; Rendell MS; Comp PC; Zhang P; Forbes WP
    Vasc Endovascular Surg; 2002; 36(2):83-91. PubMed ID: 11951094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials.
    Regensteiner JG; Ware JE; McCarthy WJ; Zhang P; Forbes WP; Heckman J; Hiatt WR
    J Am Geriatr Soc; 2002 Dec; 50(12):1939-46. PubMed ID: 12473004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication.
    Thompson PD; Zimet R; Forbes WP; Zhang P
    Am J Cardiol; 2002 Dec; 90(12):1314-9. PubMed ID: 12480040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease.
    Squires H; Simpson E; Meng Y; Harnan S; Stevens J; Wong R; Thomas S; Michaels J; Stansby G
    Health Technol Assess; 2011 Dec; 15(40):1-210. PubMed ID: 22142554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cilostazol for intermittent claudication.
    Bedenis R; Stewart M; Cleanthis M; Robless P; Mikhailidis DP; Stansby G
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD003748. PubMed ID: 25358850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6.
    Lee TM; Su SF; Hwang JJ; Tseng CD; Chen MF; Lee YT; Wang SS
    Atherosclerosis; 2001 Oct; 158(2):471-6. PubMed ID: 11583728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical manifestation of atherosclerotic peripheral arterial disease and the role of cilostazol in treatment of intermittent claudication.
    Grouse JR; Allan MC; Elam MB
    J Clin Pharmacol; 2002 Dec; 42(12):1291-8. PubMed ID: 12463722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease.
    Money SR; Herd JA; Isaacsohn JL; Davidson M; Cutler B; Heckman J; Forbes WP
    J Vasc Surg; 1998 Feb; 27(2):267-74; discussion 274-5. PubMed ID: 9510281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial.
    Beebe HG; Dawson DL; Cutler BS; Herd JA; Strandness DE; Bortey EB; Forbes WP
    Arch Intern Med; 1999 Sep; 159(17):2041-50. PubMed ID: 10510990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cilostazol: treatment of intermittent claudication.
    Reilly MP; Mohler ER
    Ann Pharmacother; 2001 Jan; 35(1):48-56. PubMed ID: 11197586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial.
    Dawson DL; Cutler BS; Meissner MH; Strandness DE
    Circulation; 1998 Aug; 98(7):678-86. PubMed ID: 9715861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endovascular revascularisation versus conservative management for intermittent claudication.
    Fakhry F; Fokkenrood HJ; Spronk S; Teijink JA; Rouwet EV; Hunink MGM
    Cochrane Database Syst Rev; 2018 Mar; 3(3):CD010512. PubMed ID: 29518253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication.
    Stevens JW; Simpson E; Harnan S; Squires H; Meng Y; Thomas S; Michaels J; Stansby G
    Br J Surg; 2012 Dec; 99(12):1630-8. PubMed ID: 23034699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cilostazol for peripheral arterial disease.
    Robless P; Mikhailidis DP; Stansby GP
    Cochrane Database Syst Rev; 2007 Jan; (1):CD003748. PubMed ID: 17253494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of cilostazol, a novel phosphodiesterase inhibitor in patients with intermittent claudication.
    Samra SS; Bajaj P; Vijayaraghavan KS; Potdar NP; Vyas D; Devani RG; Ballary C; Desai A
    J Indian Med Assoc; 2003 Sep; 101(9):561-2, 564. PubMed ID: 15168999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cilostazol for peripheral arterial disease.
    Robless P; Mikhailidis DP; Stansby GP
    Cochrane Database Syst Rev; 2008 Jan; (1):CD003748. PubMed ID: 18254032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cilostazol: a review of its use in intermittent claudication.
    Chapman TM; Goa KL
    Am J Cardiovasc Drugs; 2003; 3(2):117-38. PubMed ID: 14727939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cilostazol: a new drug in the treatment intermittent claudication.
    Kumar M; Bhattacharya V
    Recent Pat Cardiovasc Drug Discov; 2007 Nov; 2(3):181-5. PubMed ID: 18221117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication.
    Lee TM; Su SF; Tsai CH; Lee YT; Wang SS
    Clin Sci (Lond); 2001 Sep; 101(3):305-11. PubMed ID: 11524048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.